Incorporation of PROs in Composite Endpoints: Is the Win Ratio the Optimal Approach?

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Astra Zeneca; Bayer AG; Bristol-Myers Squibb; Medtronic; Merck/Schering Plough; Novartis; Applied Therapeutics; 3ivelabs; Abbott; Amgen; Relypsa; American Regent; Boehringer Ingelheim; Cardiac Dimension; Cardior; Cytokinetics; Edwards, Element; Faraday; Imbria; Innolife; Inventiva,; Ionis; Janssen, LivaNova, Lexicon, Medtronic, Merck, Novo Nordisk, Otsuka, Occlutech, PharmaCosmos, Roche, Sanofi, Secretome, Sequana, Tricog, Vifor